227 related articles for article (PubMed ID: 18030362)
1. Origin of androgen-insensitive poorly differentiated tumors in the transgenic adenocarcinoma of mouse prostate model.
Huss WJ; Gray DR; Tavakoli K; Marmillion ME; Durham LE; Johnson MA; Greenberg NM; Smith GJ
Neoplasia; 2007 Nov; 9(11):938-50. PubMed ID: 18030362
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the autochthonous transgenic adenocarcinoma of the mouse prostate (TRAMP) as a model to study effects of castration therapy.
Wikström P; Lindahl C; Bergh A
Prostate; 2005 Feb; 62(2):148-64. PubMed ID: 15389804
[TBL] [Abstract][Full Text] [Related]
3. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
Kaplan PJ; Mohan S; Cohen P; Foster BA; Greenberg NM
Cancer Res; 1999 May; 59(9):2203-9. PubMed ID: 10232609
[TBL] [Abstract][Full Text] [Related]
4. Broadening of transgenic adenocarcinoma of the mouse prostate (TRAMP) model to represent late stage androgen depletion independent cancer.
Jeet V; Ow K; Doherty E; Curley B; Russell PJ; Khatri A
Prostate; 2008 Apr; 68(5):548-62. PubMed ID: 18247402
[TBL] [Abstract][Full Text] [Related]
5. Knockin of SV40 Tag oncogene in a mouse adenocarcinoma of the prostate model demonstrates advantageous features over the transgenic model.
Duan W; Gabril MY; Moussa M; Chan FL; Sakai H; Fong G; Xuan JW
Oncogene; 2005 Feb; 24(9):1510-24. PubMed ID: 15674347
[TBL] [Abstract][Full Text] [Related]
6. Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer.
Chiaverotti T; Couto SS; Donjacour A; Mao JH; Nagase H; Cardiff RD; Cunha GR; Balmain A
Am J Pathol; 2008 Jan; 172(1):236-46. PubMed ID: 18156212
[TBL] [Abstract][Full Text] [Related]
7. Clonal deletion of simian virus 40 large T antigen-specific T cells in the transgenic adenocarcinoma of mouse prostate mice: an important role for clonal deletion in shaping the repertoire of T cells specific for antigens overexpressed in solid tumors.
Zheng X; Gao JX; Zhang H; Geiger TL; Liu Y; Zheng P
J Immunol; 2002 Nov; 169(9):4761-9. PubMed ID: 12391185
[TBL] [Abstract][Full Text] [Related]
8. Androgen-independent prostate cancer progression in the TRAMP model.
Gingrich JR; Barrios RJ; Kattan MW; Nahm HS; Finegold MJ; Greenberg NM
Cancer Res; 1997 Nov; 57(21):4687-91. PubMed ID: 9354422
[TBL] [Abstract][Full Text] [Related]
9. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.
Masumori N; Thomas TZ; Chaurand P; Case T; Paul M; Kasper S; Caprioli RM; Tsukamoto T; Shappell SB; Matusik RJ
Cancer Res; 2001 Mar; 61(5):2239-49. PubMed ID: 11280793
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer progression, metastasis, and gene expression in transgenic mice.
Perez-Stable C; Altman NH; Mehta PP; Deftos LJ; Roos BA
Cancer Res; 1997 Mar; 57(5):900-6. PubMed ID: 9041192
[TBL] [Abstract][Full Text] [Related]
11. Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer.
Kasper S; Sheppard PC; Yan Y; Pettigrew N; Borowsky AD; Prins GS; Dodd JG; Duckworth ML; Matusik RJ
Lab Invest; 1998 Mar; 78(3):319-33. PubMed ID: 9520945
[TBL] [Abstract][Full Text] [Related]
12. An investigation of the effects of late-onset dietary restriction on prostate cancer development in the TRAMP mouse.
Suttie AW; Dinse GE; Nyska A; Moser GJ; Goldsworthy TL; Maronpot RR
Toxicol Pathol; 2005; 33(3):386-97. PubMed ID: 15805078
[TBL] [Abstract][Full Text] [Related]
13. Dysfunctional transforming growth factor-beta receptor II accelerates prostate tumorigenesis in the TRAMP mouse model.
Pu H; Collazo J; Jones E; Gayheart D; Sakamoto S; Vogt A; Mitchell B; Kyprianou N
Cancer Res; 2009 Sep; 69(18):7366-74. PubMed ID: 19738062
[TBL] [Abstract][Full Text] [Related]
14. Genetic ablation of the amplified-in-breast cancer 1 inhibits spontaneous prostate cancer progression in mice.
Chung AC; Zhou S; Liao L; Tien JC; Greenberg NM; Xu J
Cancer Res; 2007 Jun; 67(12):5965-75. PubMed ID: 17575167
[TBL] [Abstract][Full Text] [Related]
15. Androgen-dependent prostate epithelial cell selection by targeting ARR(2)PBneo to the LPB-Tag model of prostate cancer.
Wang Y; Kasper S; Yuan J; Jin RJ; Zhang J; Ishii K; Wills ML; Hayward SW; Matusik RJ
Lab Invest; 2006 Oct; 86(10):1074-88. PubMed ID: 16894353
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer resistance protein-mediated efflux of androgen in putative benign and malignant prostate stem cells.
Huss WJ; Gray DR; Greenberg NM; Mohler JL; Smith GJ
Cancer Res; 2005 Aug; 65(15):6640-50. PubMed ID: 16061644
[TBL] [Abstract][Full Text] [Related]
17. Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer.
Kasper S; Sheppard PC; Yan Y; Pettigrew N; Borowsky AD; Prins GS; Dodd JG; Duckworth ML; Matusik RJ
Lab Invest; 1998 Jun; 78(6):i-xv. PubMed ID: 9645768
[TBL] [Abstract][Full Text] [Related]
18. The steroid receptor coactivator-3 is required for developing neuroendocrine tumor in the mouse prostate.
Tien JC; Liao L; Liu Y; Liu Z; Lee DK; Wang F; Xu J
Int J Biol Sci; 2014; 10(10):1116-27. PubMed ID: 25332686
[TBL] [Abstract][Full Text] [Related]
19. Immunization against luteinizing hormone-releasing hormone fusion proteins does not decrease prostate cancer in the transgenic adenocarcinoma mouse prostate model.
Hill RE; de Avila DM; Bertrand KP; Greenberg NM; Reeves JJ
Exp Biol Med (Maywood); 2003 Jul; 228(7):818-22. PubMed ID: 12876301
[TBL] [Abstract][Full Text] [Related]
20. Development of PIN and prostate adenocarcinoma cell lines: a model system for multistage tumor progression.
Soares CR; Shibata MA; Green JE; Jorcyk CL
Neoplasia; 2002; 4(2):112-20. PubMed ID: 11896566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]